Enliven Therapeutics Announces Initial Data From Ongoing Phase 1b ENABLE Clinical Trial Evaluating ELVN-001 In Patients With CML That Is Relapsed, Refractory Or Intolerant To Available TKIs

Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts

ELVN-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels evaluated, consistent with previously reported data

Data further reinforce ELVN-001's positioning as the potentially best-in-class active-site TKI in CML

Multiple key data, regulatory and operational catalysts expected in 2026

BOULDER, Colo., Jan. 8, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractory or intolerant to available tyrosine kinase inhibitors (TKIs)